Wearable Injectors Market Size ($13,880.88Mn by 2027) Lead by On-Body

On Jan 20, 2022

The wearable injectors market size to reach US$ 13,880.88 million by 2027 from US$ 5,791.23 million in 2019 to grow at a CAGR of 11.6% during 2020–2027.

New York, Jan. 21, 2022 (GLOBE NEWSWIRE) — According to our new research study on “Wearable Injectors Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type (On-Body Injectors and Off-Body Injectors); Application (Diabetes, Oncology, Cardiovascular Diseases, Autoimmune Diseases, and Other Applications); End User (Hospitals and Clinics, Homecare Setting, and Other End Users); and Geography”. The global wearable injectors market growth is driven by the increasing chronic diseases prevalence, technological advancements and design development, and conventional drug delivery system limitations. However, lack of adoption in emerging countries is a major factor hindering the market growth.

Get Exclusive Sample Pages of Wearable Injectors Market Size – COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPMD00002677/

Report Coverage	Details
Market Size Value in	US$ 5,791.23 Million in 2019
Market Size Value by	US$ 13,880.88 Million by 2027
Growth rate	CAGR of 11.6% from 2020-2027
Forecast Period	2020-2027
Base Year	2020
No. of Pages	184
No. Tables	72
No. of Charts & Figures	69
Historical data available	Yes
Segments covered	Type ; Application ; End User ; and Geography
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Wearable Injectors Market: Competition Landscape and Key Developments
Amgen, Inc., Medtronic, BD, Insulet Corporation, Gerresheimer AG (Sensile Medical), West Pharmaceutical Services, Inc., Ypsomed AG, Tandem Diabetes Care, Inc., Cequr SA, Debiotech S.A, Elcam Medical, and VALERITAS, INC. are among the key companies operating in the wearable injectors market. These players are focusing on the expansion and diversification of their market presence and the acquisition of a new customer base, thereby tapping prevailing business opportunities.

In April 2020, Zealand Pharma A/S acquired all assets of Valeritas Holdings, Inc. for the cash purchase of about US$ 23 million. This acquisition has helped to extend its business from its existing pharmaceutical business.

Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPMD00002677/

In June 2018, Medtronic launched MiniMed(TM) 670G Performance Guarantee Program for employers and payers. It is developed to lower the costs for diabetes-related complications.

In July 2018, Sensile Medical, Sanofi, and Verily (formerly Google Life Sciences) joined forces for developing and commercialization of the connected insulin patch pump. This partnership between three parties is focused on developing and commercializing a new generation of…